Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBI-608 plus nab-paclitaxel + gemcitabine vs nab-paclitaxel + gemcitabine in metastatic pancreatic ductal adenocarcinoma
CTR20170651Phase 3Active
- Sponsor
- Biotechnology Company
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of napabucasin in pancreatic adenocarcinoma (PDAC), sponsored by Biotechnology Company. Started Sep 2017; status: active.
02
Drugs
napabucasin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20170651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170651.